泰州厚德奥科科技有限公司

Taizhou Houde Aoke Technology Co., Ltd. is a clinical-stage Chinese biotechnology company focused on developing innovative immunotherapies for oncology. Founded in 2018 and headquartered in Taizhou, China, the company operates as a subsidiary of Lepu Biopharma, which acquired a 70% controlling interest in June 2018. The company's lead clinical asset is LP002, a humanized monoclonal antibody targeting programmed cell death 1 ligand 1 (PD-L1) that was exclusively in-licensed from I-Mab Biopharma. LP002 is currently undergoing Phase 2 clinical development for multiple cancer indications, including extensive-stage small cell lung cancer (ES-SCLC) and primary mediastinal large B-cell lymphoma (PMBCL). Additionally, the company is exploring combination regimens of LP002 with other therapies, such as oncolytic viruses and chemotherapy, to address unmet medical needs in solid tumors.